Epia Neuro's Innovative Approach to Stroke Rehabilitation

Epia Neuro is pioneering a brain-computer interface (BCI) designed to help stroke patients recover movement in their hands. This technology joins a rapidly growing field, with significant recent investment in companies like Neuralink and Merge Labs.

How the Brain-Computer Interface Works

Decoding Neural Signals

Epia’s disk-shaped implant is surgically placed in the skull and detects brain signals associated with the intention to move. These signals are then translated by artificial intelligence (AI) algorithms, combined with data from sensors on a grip-assist motorized glove, to predict and drive hand movements.

“These patients have very weak grip. It's a very common problem,” explains Michel Maharbiz, Epia’s CEO and a professor at UC Berkeley. “If you could just give them the grip back reliably, an enormous number of things would open up in their daily life.”

Leveraging Neuroplasticity

The device capitalizes on neuroplasticity – the brain’s ability to adapt and form new connections. Following a stroke, damage to the motor area can cause paralysis or weakness. Epia’s implant bypasses this damage by collecting signals from healthy brain areas and translating them into movement via the glove.

“We can train the system to learn the user's intent with regards to the function they're trying to compensate for,” Maharbiz adds. Repeated use is intended to strengthen neural pathways, potentially reducing reliance on the glove over time.

Distinction from Existing Technologies

A Rehabilitative Focus

David Lin, a neurologist at Massachusetts General Hospital, highlights the difference between assistive BCIs and rehabilitative ones. “That's different from a rehabilitative solution, where using that device in and of itself leads to plasticity of the brain…so that once you take the glove away, that the native function of the arm and hand gets better.”

Addressing Scalability Challenges

A key challenge for BCI technology is making it accessible. Companies like Neuralink and Synchron are exploring different implantation methods to minimize risk and complexity. Epia’s procedure involves removing a small piece of skull and replacing it with the implant, taking less than an hour.

Clinical Trials and Future Outlook

Previous Research & Current Plans

The Food and Drug Administration has previously authorized a similar device, IpsiHand, but that study lacked a control group. Epia Neuro is planning a first-in-human demonstration at Lenox Hill Hospital in New York later this year, with further tests planned at other sites by the end of 2026.

The implant is designed to be upgradable and is recharged wirelessly via a headset every few days.